Acura Pharmaceuticals Launches Next Generation Cold Medicine to Aid in the Fight Against Meth

Nexafed(R)'s Abuse-Deterrent Technology Disrupts Conversion of Pseudoephedrine to Dangerous Illegal Drug Methamphetamine Without Compromising Effective Nasal-Congestion Relief

Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR ) today announced the launch of Nexafed® [pseudoephedrine hydrochloride (HCl)], a 30 mg immediate-release next generation pseudoephedrine product, combining effective nasal-congestion relief with a unique technology that disrupts the conversion of pseudoephedrine into the dangerous drug, methamphetamine. Nexafed® is now available to national and regional drug wholesalers and will be available to pharmacies soon. This is the second of two products to reach the market that utilize Acura's abuse-deterrent technologies.

Pernix Therapeutics Announces Agreement to Acquire Somaxon Pharmaceuticals, Inc.

Somaxon Shareholders to Receive $25 Million in Pernix Common Stock

Pernix Management to Host a Conference Call Today at 9:00 a.m. EST

Pernix Therapeutics Holdings, Inc. ("Pernix") (NYSE MKT:PTX) and Somaxon Pharmaceuticals, Inc. ("Somaxon") (SOMX) today announced that they have entered into a definitive merger agreement for Pernix to acquire Somaxon in a stock-for-stock transaction with a total equity value of $25 million.

Under the terms of the agreement, which has been unanimously approved by the boards of directors of both companies, Somaxon stockholders will receive aggregate consideration equal to $25 million in Pernix common stock.

Final Data from Celldex Therapeutic’s CDX-011 Phase 2 Study in Metastatic Breast Cancer Supports Overall Survival Benefit in Patients with High GPNMB Expression

--Broad activity with greatest benefit in patients with high GPNMB-expressing triple negative breast cancer--
--Data presented today in a poster session at San Antonio Breast Cancer  Symposium--

Celldex Therapeutics, Inc. (CLDX) today announced final results from the Company’s randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer. CDX-011 is an antibody-drug conjugate that targets and binds to GPNMB, a specific protein that is expressed in breast cancer which promotes the migration, invasion and metastasis of the disease.

Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Hematology Annual Meeting

Cyclacel Pharmaceuticals, Inc. (CYCC) (CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders announced today that updated Phase 3 clinical trial results for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML) treated with sapacitabine and decitabine administered in alternating cycles will be presented at a poster presentation during the 54^th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, on Sunday, December 9, 2012.